Skip to main content

Advertisement

Table 3 Univariate and multivariate analyses for the PFS and OS of patients with tissue detected mutation and the use of TKIs as first-line therapy

From: Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21

Variable PFS OS
Univariate Multivariate Univariate Multivariate
HR (95% CI) P valuea HR (95% CI) P valuea HR (95% CI) P valuea HR (95% CI) P valuea
Age 1.000 (0.986–1.014) 0.980 0.993 (0.977–1.009) 0.381 1.008 (0.987–1.029) 0.480 0.996 (0.973–1.020) 0.757
Sex (men vs. women) 1.149 (0.830–1.590) 0.404 1.520 (0.916–2.522) 0.105 1.540 (0.992–2.393) 0.055 1.776 (0.890–3.544) 0.103
Smoking status (ever vs. never) 0.907 (0.628–1.311) 0.604 0.616 (0.363–1.044) 0.072 1.299 (0.807–2.091) 0.282 0.835 (0.405–1.722) 0.626
ECOG PS (2 vs. 0-1) 0.969 (0.523–1.796) 0.921 1.019 (0.536–1.935) 0.955 1.054 (0.454–2.447) 0.903 1.281 (0.531–3.091) 0.582
EGFR-TKI (erlotinib vs. gefitinib) 0.828 (0.531–1.291) 0.405 0.765 (0.448–1.307) 0.327 1.862 (0.581–5.962) 0.295 0.756 (0.357–1.603) 0.466
EGFR-TKI (icotinib vs. gefitinib) 0.652 (0.359–1.184) 0.160 0.702 (0.362–1.361) 0.295 1.917 (0.551–6.664) 0.306 0.255 (0.063–1.037) 0.056
Stage (IIIB vs. IV) 0.552 (0.203–1.498) 0.243 0.402 (0.119–1.356) 0.142 0.878 (0.276–2.795) 0.826 0.600 (0.144–2.506) 0.483
EGFR mutation (exon 19 del vs. L858R mutation) 0.705 (0.509–0.976) 0.035 0.631 (0.432–0.920) 0.017 0.878 (0.563–1.370) 0.566 0.671 (0.397–1.133) 0.135
  1. PFS progression-free survival, OS overall survival, HR hazard ratio, 95% CI 95% confidence interval, ECOG Eastern Cooperative Oncology Group, PS performance status, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor
  2. aAnalyzed by using univariate and multivariate COX regression adjusted for age, sex, smoking status, ECOG PS, EGFR-TKIs, and stage